Name of new malaria vaccine

The new malaria vaccine that has been approved by the World Health Organization (WHO) is called RTS,S. It is also known as Mosquirix.

RTS,S is a recombinant vaccine that is designed to protect against Plasmodium falciparum, the most deadly form of malaria. It is the first vaccine to be approved for use in children in areas where malaria is common.

The vaccine was developed by GlaxoSmithKline (GSK) and has been shown to be effective in reducing the risk of severe malaria and death in children. It is given in a series of four doses, with the first dose given at 6 weeks of age and the remaining doses given at 10 weeks, 14 weeks, and 18 months.

RTS,S has been approved for use in children aged 6 weeks to 17 months in areas where malaria is endemic. It is not recommended for use in children under 6 weeks of age or in areas where malaria is not common.

It's worth noting that RTS,S is not a 100% effective vaccine, and it's not a cure for malaria. However, it is an important tool in the fight against malaria, and it has the potential to save thousands of lives each year.